IntegenX is the market leader of Rapid DNA technology for human identification in forensics and law enforcement applications. IntegenX’s RapidHIT technologies integrate advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer solutions for DNA-based human identity testing. The RapidHIT ID System for Crime Labs generates lab-...
Apertor creates novel molecular glues for therapeutic applications in multiple disease areas. The company applies a world-class synthetic biology platform using non-model organisms, a deep knowledge of complex natural products relevant to human health, and a computational pipeline enabled by structure-guided design. The result is a first-in-class approach to solving important pharmacological problems and delivering new, high-value treatment options for patients. The company was co-founded by UC Berkeley Professor of Chemical & Biomolecular Engineering and of...
Epigenetic Gene Editing is a gene editing tools company dedicated to improvements in CRISPR-Cas9 editing by providing a fusion protein kit to gene editing companies.
Brief Description Pow.Bio provides intelligent fermentation services for industrial and synthetic biology. The company's services combine continuous fermentation with advanced control methodology to quickly optimize the fermentation process and deliver high yields at low cost. The scale runs from 1-100 liter capacity for bacteria, yeast, and filamentous fungi.
Brief Description Measuring changes in temperature and strain distributed along the length of an optical fiber with Brillouin optical time-domain reflectometry for civil engineering projects. Inventors Bo Li, Linqing Luo, Kenichi Soga, Jize Yan, Yifei Yu
Brief Description Synvivia is an early-stage Synthetic Biology startup located in QB3-EBIC in Berkeley, CA. Synvivia's technology was developed at UC Berkeley with grants from the NSF and DARPA. The work was published in ACS Synthetic Biology and featured as an Editor’s Choice in Science Magazine.
Synvivia has exclusive license to IP in all fields of use. Backed by Y Combinator, the National Institutes of Health, and industrial partnership, Synvivia is building genetically encoded biocontainment technologies that will enable the widespread use of synthetic biology outside of the laboratory...
Tenaya Therapeutics is shaping the future of heart disease treatment driven by a mission to discover, develop, and deliver curative therapies that address the underlying drivers of heart disease. Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine. Founded in 2016 by leading cardiology researchers at the Gladstone Institutes and UT Southwestern, Tenaya is backed by a top-tier syndicate of investors.
Rejuvenation therapy based on a modified version of an already FDA-approved plasma exchange technique known as plasmapheresis, in which a machine separates the plasma (the liquid part of the blood) from the blood cells and then returns the blood to the person receiving treatment. The company's approach, called next gen-apheresis, promises to spur the rejuvenation of organs and tissues as people age.
Timeline 2019. Company founded Inventors
Irina Conboy, Michael Conboy, Wendy Cousin, Christian Elabd, Yutong Liu, Melod Mehdipour, David...